StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by NewToInvesting7on Sep 19, 2020 8:47am

283 Views

Post# 31586645

RE:Thomson Reuters analyst issues buy for SZLS

I am not sure I follow SAGDollar. I do see the buy rating, but I thought that it was the Clarus buy rating that is being reported. Regardless, I think the Reuters link is an awesome find, mainly because I saw the following under the SZLS "all listing" section:

Symbol	Exchange	Price	Change	As of
SZLS.TO	The Toronto Stock Exchange	0.87CAD	+20.83%	3:59 PM EDT
GNWSD.PK	OTC MARKETS GROUP L1 AND L2	0.65USD	+25.00%	3:34 PM EDT
SZLS.CXC	Nasdaq CXC	0.94CAD	+30.56%	12:00 AM EDT